{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:19:32Z","timestamp":1790857172449,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.jaad.2010.02.059","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T06:40:55Z","timestamp":1284705655000},"page":"563-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cutaneous toxicities of antiretroviral therapy for HIV"],"prefix":"10.1016","volume":"63","author":[{"given":"Camille E.","family":"Introcaso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet M.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.02.059_bib1","unstructured":"Derisi M, Ballard C, Abulhosn K, Colwell B, Mathews WC. Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated rash (abstract). Presented at The 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 2, 2000."},{"key":"10.1016\/j.jaad.2010.02.059_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0149-2918(98)80105-7","article-title":"Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection","volume":"20","author":"Pollard","year":"1998","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2010.02.059_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","article-title":"Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs","volume":"19","author":"Ananworanich","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(98)24008-6","article-title":"Nevirapine-associated Stevens\u2013Johnson syndrome","volume":"351","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.02.059_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(07)61027-7","article-title":"Clinical update: adverse effects of antiretroviral therapy","volume":"370","author":"Calmy","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.02.059_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00126334-200402010-00003","article-title":"Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non\u2013HIV-infected individuals","volume":"35","author":"Patel","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.02.059_bib7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/00126334-200407010-00002","article-title":"Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022","volume":"36","author":"Hitti","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.02.059_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/QAI.0b013e318032bbee","article-title":"Antiretroviral-associated toxicity among HIV-1\u2013seropositive pregnant women in mozambique receiving nevirapine-based regimens","volume":"44","author":"Jamisse","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.02.059_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART","volume":"19","author":"van Leth","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib10","first-page":"1","article-title":"Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis","volume":"54","author":"Panlilio","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2010.02.059_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1468-1293.2007.00477.x","article-title":"Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women","volume":"8","author":"Phanuphak","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/00002030-200108170-00018","article-title":"Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy","volume":"15","author":"Antinori","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1601-0825.2001.70401.x","article-title":"Orofacial effects of antiretroviral therapies","volume":"7","author":"Scully","year":"2001","journal-title":"Oral Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1529-8019.2005.05004.x","article-title":"Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients","volume":"18","author":"Kong","year":"2005","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.02.059_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5005\/jcdp-9-1-84","article-title":"Oral adverse effects due to the use of nevirapine","volume":"9","author":"Moura","year":"2008","journal-title":"J Contemp Dent Pract"},{"key":"10.1016\/j.jaad.2010.02.059_bib16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1525-1470.2007.00605.x","article-title":"Nevirapine-induced Stevens-Johnson syndrome in a pediatric patient","volume":"25","author":"Mason","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00042560-200109010-00003","article-title":"Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09\/99 study","volume":"28","author":"Knobel","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.02.059_bib19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/00002030-199903110-00013","article-title":"Incidence of rash and discontinuation of nevirapine using two different escalating initial doses","volume":"13","author":"Anton","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1128\/AAC.40.7.1657","article-title":"Randomized, controlled phase I\/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients","volume":"40","author":"Davey","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaad.2010.02.059_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/135965359900400107","article-title":"Acute hypersensitivity with delavirdine","volume":"4","author":"Mills","year":"1999","journal-title":"Antivir Ther (Lond)"},{"key":"10.1016\/j.jaad.2010.02.059_bib22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003495-200060060-00013","article-title":"Delavirdine: a review of its use in HIV infection","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2010.02.059_bib23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJM199912163412502","article-title":"Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team","volume":"341","author":"Starr","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib24","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib25","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e318033ffa1","article-title":"Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda","volume":"44","author":"Forna","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jaad.2010.02.059_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","article-title":"Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients","volume":"3","author":"Perez-Molina","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jaad.2010.02.059_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.02.059_bib29","series-title":"Sustiva [package insert]","year":"2008"},{"key":"10.1016\/j.jaad.2010.02.059_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1473-3099(07)70262-1","article-title":"Is it safe to switch between efavirenz and nevirapine in the event of toxicity?","volume":"7","author":"Mehta","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.02.059_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.02.059_bib33","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32805e8776","article-title":"Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis","volume":"21","author":"Nadler","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib34","series-title":"Intelence [package insert]","year":"2008"},{"key":"10.1016\/j.jaad.2010.02.059_bib35","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib36","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib37","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/00365540410021018a","article-title":"Acute hypersensitivity reaction to enfuvurtide upon re-challenge","volume":"36","author":"Beilke","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib38","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1086\/425502","article-title":"Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man","volume":"39","author":"DeSimone","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.aids.0000161779.23191.e5","article-title":"Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction","volume":"19","author":"Shahar","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib40","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0190-9622(03)02099-1","article-title":"Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide","volume":"49","author":"Ball","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0149-2918(08)80048-3","article-title":"Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection","volume":"30","author":"Lieberman-Blum","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2010.02.059_bib42","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2007.43.12.1146063","article-title":"Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1","volume":"43","author":"Evering","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jaad.2010.02.059_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.02.059_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1086\/499356","article-title":"Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort","volume":"42","author":"Ratnam","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-4632.2007.03520.x","article-title":"Current status of HIV infection: a review for non-HIV-treating physicians","volume":"46","author":"Knoll","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00128071-200708040-00004","article-title":"Dermatologic adverse effects of antiretroviral therapy: recognition and management","volume":"8","author":"Luther","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/519504","article-title":"A case of efflorescence of cutaneous warts as\u00a0a\u00a0manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient","volume":"45","author":"Kerob","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2133.2007.08094.x","article-title":"Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy","volume":"157","author":"Handisurya","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1468-3083.2001.00337.x","article-title":"Dermatological immune restoration syndrome: does it exist?","volume":"15","author":"Handa","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.02.059_bib50","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1097\/QAD.0b013e3282887ea7","article-title":"Increased incidence of cutaneous mycoses after HAART initiation: a benign form of immune reconstitution disease?","volume":"21","author":"Nacher","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jaad.2010.02.059_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.136.1.129","article-title":"Cutaneous ulcer caused by Mycobacterium avium and recurrent genital herpes after highly active antiretroviral therapy","volume":"136","author":"Pelgrom","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib52","first-page":"452","article-title":"Case report. Severe cutaneous ulceration secondary to cytomegalovirus inclusion disease during successful immune reconstitution with HAART","volume":"12","author":"Qazi","year":"2002","journal-title":"AIDS Read"},{"key":"10.1016\/j.jaad.2010.02.059_bib53","first-page":"1103","article-title":"Cutaneous warts in HIV-positive patients undergoing highly active antiretroviral therapy","volume":"137","author":"Rodrigues","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/INF.0b013e3180618c2d","article-title":"Cutaneous Mycobacterium avium complex infection as a manifestation of the immune reconstitution syndrome in a human immunodeficiency virus-infected child","volume":"26","author":"Steenhoff","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2010.02.059_bib55","first-page":"1","article-title":"Cutaneous cryptococcosis as a rare manifestation of the immune reconstitution syndrome in an HIV-1-infected patient","volume":"62","author":"Gasiorowski","year":"2008","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"10.1016\/j.jaad.2010.02.059_bib56","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2133.2007.08157.x","article-title":"Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome","volume":"157","author":"Antinori","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QCO.0b013e3282a6463d","article-title":"Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy","volume":"20","author":"Lawn","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1086\/381033","article-title":"Pyomyositis and cutaneous abscesses due to mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS","volume":"38","author":"Lawn","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2010.02.059_bib59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1258\/0956462052932647","article-title":"Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation","volume":"16","author":"Crane","year":"2005","journal-title":"Int J STD AIDS"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2010.02.059_bib60","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.jaad.2004.04.020","article-title":"Tumid lupus erythematosus occurring following highly active antiretroviral therapy for HIV infection: a manifestation of immune restoration","volume":"51","author":"Chamberlain","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-4632.2006.02545.x","article-title":"Cutaneous and pulmonary sarcoidosis in a patient with HIV after highly active antiretroviral therapy","volume":"46","author":"Roustan","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib62","first-page":"669","article-title":"Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: a manifestation of the immune restoration syndrome","volume":"137","author":"Silvestre","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.02.059_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/sti.77.2.149-a","article-title":"Deterioration of disseminated cutaneous mycobacterium avium complex infection with a leukaemoid reaction following institution of highly active antiretroviral therapy","volume":"77","author":"Brown","year":"2001","journal-title":"Sex Transm Infect"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:17:08Z","timestamp":1759270628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0190962210003646"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.02.059","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous toxicities of antiretroviral therapy for HIV","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.02.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}